-
48 8.0
Immune-mediated toxicities (irAEs) in immune checkpoint inhibitor (ICI) therapy in various combinations: a real-world sample
-
37 6.15
Sociodemographic predictors of palliative care utilization across the MedStar Health system
-
46 5.8
Clinical characterization and association with autoimmunity in immune checkpoint inhibitor (ICI)-mediated thyroid dysfunction in a real-world sample